Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-01

Clinical Trial Update: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas [Phase 2]

View source ↗

Summary

Phase 2 trial of axitinib in Neurofibromatosis Type 2 with progressive vestibular schwannomas completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Axitinib (Axitinib)

Snippet

Sponsor: NYU Langone Health | Conditions: Neurofibromatosis Type 2, Vestibular Schwannomas | Phase 2 | Status: COMPLETED | Results posted: 2021-12-01